The challenge facing the pharmaceutical industry is to prioritize which of the myriad of possible targets it is productive to attack. Such decisions will be made on the basis of homology reasoning to known genes, as well as using information gleaned from new techniques that characterize the localization and temporal expression of the identified genes. For example, genes that are preferentially expressed in diseased tissue, compared to healthy tissue, are likely to be the new targets of the pharmaceutical industry (ref.
2). The industry is therefore in the throes of a revolution as the discovery process now begins with a gene sequence rather than with the traditional disease focus. The magnitude of the opportunity is illustrated by the number of EST's available for analysis in SmithKline Beecham's data bases. These comprise sequences generated by its collaborators at Human Genome Sciences (HGS) and augmented by those in the public data bases.
Over 1 million EST's are in the SBRIGS data base and this is increasing at the rate of 20,000 per month
Seven Transmembrane ReceDtors (7TMR's)
Seven transmembrane receptors contain sequences that span the cell membrane seven times so that the N terminal portion is extracellular and the C terminal portion is intracellular. Such receptors are G protein coupled and the coupling occurs via the intracellular loops. The superfamily of 7TMR's, also known as G-protein coupled receptors, has historically proven to be a rich source of drug targets. Some examples of clinically and commercially successful drugs which are ligands for this superfamily are shown below. Furthermore, newly-discovered members of the superfamily continue to provide molecular targets for recent drug discovery programs and a number of selective antagonists are under development. In a recent example from SB, a research effort directed at the endothelin A and B receptors (ETA and ETB) has led to several drug candidates under development. The SB program required the synthesis of over 325 compounds prepared in an interative synthesidtesting paradigm to achieve the first development candidate. In total, 1000 compounds were made over several years in the search for and optimization of different structural types. The structure of one of these, 1 (SB 209670) , is shown below (ref.
3).
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It therefore is evident that the identification of novel 7TMRs and their ligands and of orphan 7TMRs (those members for which the endogenous ligand is unknown) may provide a likely starting point for new drug discovery programs. Using motifs characteristic of members of the 7TMR superfamily to search the SB/HGS data base, followed by cloning the full length genes, scientists at SB have identified over 50 novel full length clones, the majority of which have been stably expressed in mammalian cells for functional studies. (D. Bergsma, et al, unpublished).
Over 50 full length orphan 7TMR's are under study at SB The Chemist's ResDonse to Genomics -Combinatorial Chemistrv
As illustrated by the magnitude of the opportunity represented by the 7TMR superfamily, the multiplicity of targets emanating from rapid high throughput sequencing of cDNA libraries cannot be addressed by "one target at a time" iterative medicinal chemistry paradigms. First, the time window of opportunity is narrow owing to competitive forces and many competitors now have access to similar information. Second, the magnitude of the problem is such that opportunities will be wasted if one is restricted to iterative methods. Third, rapid identification of antagonists for members of, say the 7TMR family, could offer tools to allow dissection of function of many of these receptors. Thus, we enter an era of "reverse pharmacology" where, in some cases, finding the antagonist first would allow the biological significance of the target to be ascribed.
Combinatorial chemistry can take on many forms. "Split and mix" procedures on solid phase lead to each solid phase particle (bead) containing only one molecular entity. Large libraries are possible, but active beads require structural deconvolution. Alternatively, the concurrent syntheses of many compounds using array technology where the individual components are spatially localized obviates deconvolution of structure. Library sizes, however, are limited by current technology. No one approach appears 36 1 superior, and SB has invested in both. The "split and mixn approach was used to great effect by Lam, et a1 (ref. 4) in the generation of a pentapeptide library using nineteen naturally-encoded amino acids to afford 195 peptides (2,476,099) on beads where each bead carries only one peptide. The library was screened in a biopanning procedure against a monoclonal antibody, as a model receptor, and high affinity peptides were isolated. The challenge facing medicinal chemists is whether the concepts illustrated in the Lam study can be extrapolated to the combinatorial preparation of "drug-like'' organic molecules.
Permissive Structures for 7TMR ligands
It has been known for some time that permissivity exists amongst ligands for the 7TMR superfamily. For example, in the biogenic amine arena, dopamine has affinity for a number of 5-HT receptors, and noradrenaline for some dopamine receptors. This promiscuity suggests that when confronted with a new member of the 7TMR superfamily one should first screen a collection of ligands previously identified as having affinity for other members of the family. Accordingly, cross screening of compound collections from other 7TMR efforts revealed that the imidazole 2, a relatively potent antagonist of the angiotensin-1 receptor had affinity for the ETA receptor. Further modification of 2 led to the potent and selective ETA antagonist 3 (ref. 5).
OCH.
-2 -3
Ki (ETA) = 400 nM
Perrnissivity amongst ligands therefore applies not only to receptors that bind the biogenic amines, but also to the 7TMRs that recognize acidic ligands. Extending the concept, faced with fifty members of the family at once as drug targets, one could consider selecting a motif common to some of these ligands and constructing a combinatorial library around that structure.
We wished to apply the "split and mix" approach to a template representative of a permissive ligand for 7TMRs. Such a resource could then be applied to the multiplicity of novel 7TMRs available from genomic approaches. The template we chose was the biphenyl structure present in the angiotensin antagonist Losartan, 4 (ref. 6 ) and in a number of ligands for ~-H T~D receptors as represented in s (ref.
7).
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Solid Phase Synthesis and Library Construction
A novel arylsilane polymer 4 has been prepared starting from a polystyrene resin so that the aryl bromide substituent allows elaboration. Library components can be released from the polymer by protodesilylation in a "traceless" fashion (ref. -6 -7
Analvtical Methods
Advances in the solid state synthesis field have been facilitated by the advent of the mass spectrometric techniques, electrospray-, matrix-assisted laser desorption-and time-of-flight mass spectrometry (ref. 12) and by magic angle spinning nmr (ref. 13). Using these techniques we are able to elucidate the structure of molecules from a single bead.
Limitations of Combinatorial Chemistrv and the Future of Medicinal Chemistrv
Unlike solution phase organic chemistry where each reaction product in a linear sequence can be purified prior to the next step, solid phase chemistry allows no purification until final release of product from the bead. It does however offer the advantage of allowing reactions to be driven to completion by using an excess of reagents that can be simply washed away from the product which remains bead-bound. Consider, however, a solid phase linear sequence with each step providing a product of 90% purity. The result after six steps would be a compound of maximum purity of 53% attached to the bead. Perhaps it is not coincidental that the longest linear solid phase syntheses thus far reported is that of Goff and Zuckerriian (ref. 9) who prepared a library of isoquinolinones in five linear steps.
Can molecules of sufficient molecular complexity to satisfy potency, selectivity and pharmacokinetic criteria for drug candidates be prepared directly by combinatorial methods? This author's opinion is that some percentage, perhaps 10 -20% of drug candidates will be identified by combinatorial means and will not require further elaboration. In the majority of cases, however, combinatorial chemistry will provide a lead which will require optimization by iterative methods. Paradoxically, the success of combinatorial cherhistry will create a greater need for resources for iterative chemistry. 
